mergers & acquisitions
Biosynex to Acquire Chembio Diagnostics for $17.2M
Biosynex will buy all of Chembio's shares at $.45 per share in an all-cash deal that merges two developers and makers of point-of-care diagnostic tests.
Sherlock Biosciences to Acquire Sense Biodetection
The firms intend to combine Sherlock's CRISPR technology and Sense's rapid molecular amplification chemistries, accelerating Sherlock's go-to-market strategy.
Among potential growth opportunities, the firm's new CEO noted hospital lab M&A and STD and cancer testing.
Both the number of mergers and acquisitions and the size of deals decreased in 2022 compared to the highs of 2021 and 2020.
Top 10 Articles on 360Dx in 2022
In 2022 readers were most interested in a story about what happened to Cepheid's GeneXpert Omni, a point-of-care platform once touted by the company.
Dec 21, 2022
Nov 22, 2022
Biocare Medical Acquires Empire Genomics
Nov 3, 2022
Werfen to Acquire Immucor for $2B
Nov 2, 2022
Oct 27, 2022
Oct 14, 2022
DiaCarta to go Public Through SPAC Merger
Oct 11, 2022
Speciality Dx Firm Sebia Acquires Zeus Scientific
Sep 23, 2022